|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5453566A
(en)
|
1986-03-28 |
1995-09-26 |
Calgene, Inc. |
Antisense regulation of gene expression in plant/cells
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
ATE115999T1
(de)
|
1987-12-15 |
1995-01-15 |
Gene Shears Pty Ltd |
Ribozyme.
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8822492D0
(en)
|
1988-09-24 |
1988-10-26 |
Considine J |
Apparatus for removing tumours from hollow organs of body
|
|
US5211657A
(en)
|
1988-11-07 |
1993-05-18 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
|
DE69030172T2
(de)
|
1990-01-26 |
1997-06-19 |
Immunomedics Inc |
Impfstoffe gegen Krebs und Infektionskrankheiten
|
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
|
US5789573A
(en)
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
|
IL108367A0
(en)
|
1993-01-27 |
1994-04-12 |
Hektoen Inst For Medical Resea |
Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
|
|
SE9301911D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptide derivatives
|
|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
|
ZA951617B
(en)
|
1994-03-04 |
1997-02-27 |
Lilly Co Eli |
Antithrombotic agents.
|
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US6011158A
(en)
|
1994-12-13 |
2000-01-04 |
Corvas International, Inc. |
Aromatic heterocyclic derivatives as enzyme inhibitors
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
|
US5866573A
(en)
|
1997-04-21 |
1999-02-02 |
Merck & Co., Inc. |
Pyrazinone thrombin inhibitors
|
|
EP1082324A4
(en)
|
1998-05-26 |
2002-01-02 |
Merck & Co Inc |
IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
|
|
AU747776B2
(en)
*
|
1998-10-30 |
2002-05-23 |
Merck & Co., Inc. |
Thrombin inhibitors
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
|
HUP0202191A3
(en)
*
|
1999-05-19 |
2003-02-28 |
Pharmacia Corp Chicago |
Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
|
|
US6653316B1
(en)
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
JP2002544263A
(ja)
*
|
1999-05-19 |
2002-12-24 |
ファルマシア・コーポレイション |
抗凝血剤としての置換多環式アリールおよびヘテロアリールウラシル
|
|
US7015230B1
(en)
*
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
|
US6664255B1
(en)
*
|
1999-05-19 |
2003-12-16 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
|
|
CN1157380C
(zh)
*
|
1999-05-19 |
2004-07-14 |
法玛西雅公司 |
可用作抗凝血剂的取代的多环芳基与杂芳基嘧啶酮
|
|
US20040072862A1
(en)
|
1999-06-04 |
2004-04-15 |
Bitler Catherine M. |
Compositions for treating ischemia-related neuronal damage
|
|
US6649592B1
(en)
|
2000-01-14 |
2003-11-18 |
Science & Technology Corporation @ Unm |
Peptide inhibitors of LFA-1/ICAM-1 interaction
|
|
WO2001079195A2
(en)
|
2000-04-14 |
2001-10-25 |
Corvas International, Inc. |
Pyridine and pyrazine derivatives as thrombin inhibitors
|
|
WO2001087851A1
(en)
*
|
2000-05-18 |
2001-11-22 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
|
JP2004516286A
(ja)
|
2000-12-18 |
2004-06-03 |
メルク エンド カムパニー インコーポレーテッド |
ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
|
|
CA2462647A1
(en)
|
2001-10-03 |
2003-04-10 |
Michael S. South |
6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
|
|
MXPA04003169A
(es)
*
|
2001-10-03 |
2004-07-08 |
Pharmacia Corp |
Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion.
|
|
EP1531757B1
(en)
|
2002-07-19 |
2016-09-07 |
Omeros Corporation |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
|
AU2003299901A1
(en)
|
2002-10-04 |
2004-05-04 |
Merck And Co., Inc. |
Thrombin inhibitors
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
EP2465534B1
(en)
|
2004-06-10 |
2017-03-29 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
DE602006010834D1
(de)
|
2005-03-16 |
2010-01-14 |
Janssen Pharmaceutica Nv |
Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
|
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
EP3150635A3
(en)
|
2009-10-16 |
2017-06-21 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
|
|
HUP1000366A2
(en)
|
2010-07-13 |
2012-03-28 |
Mta Enzimologiai Intezet |
Novel proteins, their production process and use tereof
|
|
DK2694108T3
(en)
|
2011-04-08 |
2018-08-20 |
Univ Leicester |
METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
|
AU2013201779B2
(en)
|
2011-05-04 |
2016-01-07 |
Omeros Corporation |
Compositions for inhibiting MASP-2 dependent complement activation
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
NZ629675A
(en)
|
2012-04-06 |
2017-02-24 |
Omeros Corp |
Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
|
PT2861246T
(pt)
|
2012-06-18 |
2021-04-05 |
Univ Leicester |
Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
|
|
AR091490A1
(es)
|
2012-06-19 |
2015-02-11 |
Bristol Myers Squibb Co |
Antagonistas de iap
|
|
WO2014057069A1
(en)
|
2012-10-10 |
2014-04-17 |
Novo Nordisk Health Care Ag |
Liquid pharmaceutical composition of factor vii polypeptide
|
|
EP2922535B1
(en)
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
|
RS61351B1
(sr)
|
2013-10-17 |
2021-02-26 |
Omeros Corp |
Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
|
|
US10266515B2
(en)
|
2013-12-30 |
2019-04-23 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
CN117398458A
(zh)
|
2015-11-09 |
2024-01-16 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
|
CA3010593C
(en)
|
2016-01-05 |
2024-02-13 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
NZ745531A
(en)
|
2016-03-31 |
2020-09-25 |
Omeros Corp |
Methods for inhibiting angiogenesis in a subject in need thereof
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
|
|
BR112020004800A2
(pt)
|
2017-09-13 |
2020-09-24 |
Amgen Inc. |
compostos de bisamida ativantes do sarcômero e seus usos
|
|
GB201805174D0
(en)
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
|
WO2019231935A1
(en)
|
2018-05-29 |
2019-12-05 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
CN115052862A
(zh)
|
2019-12-04 |
2022-09-13 |
奥默罗斯公司 |
Masp-2抑制剂和使用方法
|
|
AU2020395306B2
(en)
|
2019-12-04 |
2025-04-24 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|
|
WO2022035997A1
(en)
|
2020-08-11 |
2022-02-17 |
Avilar Therapeutics, Inc. |
In vivo assembly of asgpr binding therapeutics
|